Home โบ Proteinuria
Proteinuria clinical trials recruiting in the U.S.
17 studies for Proteinuria are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX5 studies
- Aurora, CO5 studies
- Miami, FL4 studies
- Los Angeles, CA3 studies
- Orlando, FL3 studies
- Salt Lake City, UT3 studies
- Cedar Rapids, IA3 studies
- Philadelphia, PA3 studies
- Boston, MA3 studies
- Washington, DC3 studies
By state
- California6 studies
- Colorado8 studies
- Florida8 studies
- Georgia4 studies
- Iowa3 studies
- Maryland3 studies
- Massachusetts4 studies
- Michigan3 studies
- Ohio3 studies
- Pennsylvania5 studies
- Texas5 studies
- Utah3 studies
Recently updated studies
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
RecruitingPhase 2
Ages 18 to 115 ยท All sexes ยท Updated Sep 29, 2026 ยท NCT06664814A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
RecruitingPhase 2
Ages 18 to 60 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07541287Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RecruitingPhase 2
Ages 18 to 90 ยท All sexes ยท Updated Sep 22, 2026 ยท NCT00977977Urinary Vitamin C Loss in Diabetic Subjects
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 65 ยท All sexes ยท Updated Sep 22, 2026 ยท NCT00071526Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
RecruitingPhase 3
Ages 2 to 18 ยท All sexes ยท Updated Sep 9, 2026 ยท NCT06994845A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Aug 13, 2026 ยท NCT07268638A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
RecruitingPhase 2
Ages 18 to 100 ยท All sexes ยท Updated Aug 10, 2026 ยท NCT07146906Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RecruitingPhase 2
Ages 18 to 100 ยท All sexes ยท Updated Jul 30, 2026 ยท NCT05268289Study of Ravulizumab in Pediatric Participants With Primary IgAN
RecruitingPhase 3
Ages 2 to 18 ยท All sexes ยท Updated Jul 30, 2026 ยท NCT07024563Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Jul 30, 2026 ยท NCT07224776Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
RecruitingPhase 3
Ages 12 to 60 ยท All sexes ยท Updated Jul 13, 2026 ยท NCT05755386Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
RecruitingPhase 3
Ages 12 to 60 ยท All sexes ยท Updated Jul 13, 2026 ยท NCT04817618Study of BHV-1400 in IgA Nephropathy
RecruitingPhase 1
Ages 18 to 65 ยท All sexes ยท Updated Jun 23, 2026 ยท NCT07054684Empagliflozin Treatment in Kidney Transplant Recipients
RecruitingPhase 4
Ages 19 and older ยท All sexes ยท Updated Apr 21, 2026 ยท NCT06013865Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
RecruitingObservational studyHealthy volunteers welcome
Ages 7 to 18 ยท All sexes ยท Updated Dec 11, 2025 ยท NCT04752293Proteinuria in Pre and Post Transplant
RecruitingObservational study
Up to age 25 ยท All sexes ยท Updated Nov 21, 2025 ยท NCT01094327Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
RecruitingObservational studyHealthy volunteers welcome
All ages ยท All sexes ยท Updated Oct 4, 2024 ยท NCT01016613From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.